To identify the cell types that mediate the anti-inflammatory and immunosuppressive effects of IVIg in vivo, we initially compared the transcriptional profiles of PBMCs, CD14+ monocytes, CD3+ T cells and CD20+ B cells isolated from CVID patients before and 6 h after IVIg infusion (Fig. 1A). The gene discussed is CD14; the disease is common variable immunodeficiency.